Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
Recent Articles
RELATED ARTICLES
-
Synagistics holds potential to enliven moribund Hong Kong SPAC market
2562.HK - Stealthy eLong Power sneaks closer to U.S. listing
-
ZG Group and Aquila aim to score Hong Kong’s first SPAC merger success
7836.HK
- CHINA BULLETIN: Services, Trade Send Positive Signals
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
